Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4175408 · 1 trial · 5 indications
Per investigator assessed Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
| Arm | Type | Description |
|---|---|---|
| Phase 1a Dose Escalation (Cohort A1) | EXPERIMENTAL | Escalating doses of LY4175408 administered intravenously (IV) |
| Phase 1a Dose Optimization (Cohort A2) | EXPERIMENTAL | Two or more doses of LY4175408 (evaluated during dose escalation) administered IV |
| Phase 1b Dose Expansion (Cohort B1) | EXPERIMENTAL | LY4175408 administered IV followed by pembrolizumab administered IV |
| Phase 1b Dose Expansion (Cohort B2) | EXPERIMENTAL | LY4175408 administered IV followed by pembrolizumab administered IV and either carboplatin administered IV or cisplatin administered IV |
| Phase 1b Dose Expansion (Cohorts C1, C2 and C3) | EXPERIMENTAL | LY4175408 administered IV |
| Name | Type | Description |
|---|---|---|
| LY4175408 | DRUG | IV infusion |
| Pembrolizumab | DRUG | IV infusion |
| Carboplatin | DRUG | IV infusion |
| Cisplatin | DRUG | IV infusion |
Inclusion Criteria: * Have one of the following advanced or metastatic solid tumor cancers: * Non-small cell lung cancer (NSCLC) * Small cell lung cancer (SCLC) * Endometrial cancer * Triple negative breast cancer (TNBC) (characterized by HR-negative disease and HER2-negative expression ac...
LY4175408 is an investigational small molecule developed by Eli Lilly and Company for the treatment of advanced solid tumors, including non-small cell lung cancer. It is currently in Phase 1 clinical development and is not yet approved for any indication. The study is biomarker selected, meaning participants are chosen based on specific tumor characteristics.
LY4175408 is being studied in non-small cell lung cancer as part of a Phase 1 trial in participants with advanced cancer. The study also enrolls patients with small cell lung carcinoma, endometrial neoplasms, metastatic tumors, and triple negative breast cancer. It remains investigational and has not been approved for treating any cancer type.
LY4175408 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company is running the Phase 1 program for this small molecule across multiple cancer types, including non-small cell lung cancer.
LY4175408 is in Phase 1 clinical development. One Phase 1 trial is currently recruiting participants, and no trials have been completed. The drug is investigational and has not received FDA approval for any indication.
LY4175408 is being evaluated in the Phase 1 trial NCT07046923, titled A Study of LY4175408 in Participants With Advanced Cancer. The trial is recruiting and plans to enroll 240 participants across the United States, China, France, Japan, South Korea, and Spain. It enrolls adults aged 18 and older of any sex.